Panacea Acquisition Corporation (NYSE:PANA) announced that its shareholders have approved its combination with drug developer Nuvation Bio at a special meeting earlier today.
No redemption information was given. The vote results were ~94% in favor of the combination with ~6% voting against the merger, with 500 shares abstaining.
Panacea expects the deal to close February 10, 2021. The combined entity will begin publicly trading on the New York Stock Exchange under the new symbols “NUVB” and “NUVBW”, respectively, on February 11, 2021.
Panacea initially announced its $1.3 billion combination with Nuvation Bio on October 21. New York-based Nuvation Bio is developing six novel treatments for a variety of cancer types.
ADVISORS
- Jefferies is acting as lead capital markets and financial advisor to Nuvation Bio.
- BMO Capital Markets, BTIG, RBC Capital Markets and Wedbush PacGrow are also acting as advisors to Nuvation Bio.
- Cooley is acting as legal counsel to Nuvation Bio.
- Cowen is acting as financial advisor to Panacea and private placement agent.
- Skadden Arps Slate Meagher & Flom is acting as legal counsel to Panacea.
Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...